Opus Genetics, Inc.
IRD
Get informed when a big investor buys or sells
+ FollowMarket Cap$383.93M
Close$
$-0.21
104.5% downside
Current Fair Value
104.5% downsideOvervalued by 104.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $383.93 Million |
|---|---|
| Enterprise Value | $330.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.8 |
| Beta | 0.62 |
| Outstanding Shares | 95,483,280 |
Return
| Return on Equity | 828.66% |
|---|---|
| Return on Assets | -115.75% |
| Return on Invested Capital | -48.87% |
Valuation & Multiples
| P/E Ratio | -3.66 |
|---|---|
| PEG | -40.07 |
| Price to Sales | - |
| Price to Book Ratio | -4.64 |
| Enterprise Value to Revenue | 64.4 |
| Enterprise Value to EBIT | -7.91 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -2.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$2.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$1.54 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ocuphire Pharma Inc
28 employees
CEO: Douglas Swirsky Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering...